SNN Stock Analysis: Buy, Sell, or Hold?
SNN - Smith & Nephew plc
$29.26
0.22 (0.76%)
▲
5d:
-1.85%
30d:
-1.71%
90d:
-4.88%
HOLD
MODERATE Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When SNN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SNN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: SNN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$52.29
Based on 6.6% avg growth
INTRINSIC VALUE TODAY
$32.47
9.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SNN is currently trading at $29.26, which is considered oversold relative to its 30-day fair value range of $29.53 to $31.45. From a valuation perspective, the stock is trading at a discount (Forward PE: 12.0) compared to its historical average (15.7). Remarkably, the market is currently pricing in an annual earnings decline of 8.7% over the next few years. This pessimistic expectation contrasts with the company's recent 5.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, SNN is in a downtrend. The price is currently testing key support at $28.71. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 59/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $33.66 (+15.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SNN is in a downtrend. The price is currently testing key support at $28.71. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 59/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $33.66 (+15.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$29.53 -
$31.45
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (59/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($33.66)
- NEUTRAL: Bottoming setup forming (59/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$29.53 -
$31.45
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$28.71
Resistance Level
$30.40
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.96
Wall Street Target
$33.66
(+15.9%)
Revenue Growth (YoY)
4.6%
Earnings Growth (YoY)
5.7%
Profit Margin
10.1%
Valuation Discount vs History
-8.7% cheaper
PE vs Historical
12.0 vs 15.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.7%
(market-implied from PE analysis)
1-Year Target
$26.51
(-9%)
2-Year Target
$24.21
(-17%)
3-Year Target
$22.10
(-24%)
3-Yr Target (if PE normalizes)
(PE: 12→16)
$29.00
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 9.1%)
$63.31
(+118%)
Base:
(SPY PE: 12.0, Growth: 9.1%)
$37.74
(+30%)
Bear:
(PE: 10.2, Growth: 9.1%)
$32.08
(+11%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (20x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 19.94 | Current EPS (TTM): $1.47
Bull Case
$53.23
(+82%)
Analyst growth 65.1%, PE expands to 21.9
Base Case
$48.39
(+65%)
Market implied 65.1%, PE stable at 19.9
Bear Case
$19.93
(-32%)
Severe decline -20.0%, PE contracts to 17.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 12.0 to 15.7
Stabilization Target:
$38.11
(+31.2%)
PE Expansion Potential:
+31.2%
Share & Embed Analysis
Last updated: August 24, 2026 4:36 AM ET
Data refreshes hourly during market hours. Next update: 5:36 AM
Data refreshes hourly during market hours. Next update: 5:36 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SNN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 49 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 53 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 48 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 31 SELL |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 37 SELL |
